Search results for "DVT"
Higher risk for DVT, PE, bleeding seen after COVID-19; long-term risk for VTE recurrence may be low
A Swedish study found that patients who had COVID-19 were at higher risk for a first deep venous thrombosis (DVT) for up to three months, pulmonary embolism (PE) for up to six months, and bleeding for up to two months, while a single-center study from France found that risk for venous thromboembolism (VTE) recurrence up to a year after COVID-19 was low.
https://immattersacp.org/weekly/archives/2022/04/12/2.htm
12 Apr 2022
First medication for severe frostbite approved
This column reviews recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2024/04/first-medication-for-severe-frostbite-approved.htm
1 Apr 2024
Patients with provoked VTE often on anticoagulation longer than recommended
Three variables were associated with receiving anticoagulation for longer than three months after a provoked venous thromboembolism (VTE): direct oral anticoagulant use, history of VTE, and history of myocardial infarction.
https://immattersacp.org/weekly/archives/2022/11/01/4.htm
1 Nov 2022
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022
Long-term anticoagulation after first unprovoked VTE associated with considerable bleeding risk
Results from a systematic review and meta-analysis provide a framework for clinicians and patients to balance the benefits and harms of extended anticoagulation for unprovoked venous thromboembolism (VTE).
https://immattersacp.org/weekly/archives/2021/09/14/4.htm
14 Sep 2021
MKSAP Quiz: Swollen leg and recent cancer treatment
A 68-year-old woman is evaluated in the emergency department for swelling in her right leg of 3 days' duration. She completed therapy for breast cancer 1 month ago. She takes no medications. Following a physical exam, what is the most appropriate test?
https://immattersacp.org/weekly/archives/2024/02/20/3.htm
20 Feb 2024
Guidelines offer 28 recommendations for initial management, secondary prevention of DVT and PE
Among other recommendations, the new guidelines from the American Society of Hematology suggest offering home treatment to low-risk patients with deep venous thrombosis (DVT) or pulmonary embolism (PE).
https://immattersacp.org/weekly/archives/2020/10/20/5.htm
20 Oct 2020
DOACs may be safe, effective for VTE prevention in patients with higher weight, BMI
Patients with first-time venous thromboembolism (VTE) who weighed 120 kg or more and had a body mass index (BMI) of 40 kg/m2 or more were not at higher risk for bleeding or recurrent VTE with direct-acting oral anticoagulants (DOACs) versus warfarin.
https://immattersacp.org/weekly/archives/2021/11/09/4.htm
9 Nov 2021
Industry-funded trial finds a direct factor X inhibitor noninferior to a low-molecular-weight heparin for cancer-associated VTE
Edoxaban was associated with a lower rate of recurrent venous thromboembolism (VTE) but a higher rate of major bleeding.
https://immattersacp.org/weekly/archives/2017/12/19/2.htm
19 Dec 2017
Low-molecular-weight heparin may not prevent VTE after knee arthroscopy or lower-leg casting, studies find
The Prevention of Thrombosis after Knee Arthroscopy (POT-KAST) and the Prevention of Thrombosis after Lower Leg Plaster Cast (POT-CAST) trials used the same methods and design to compare a prophylactic dose of low-molecular-weight heparin or no anticoagulant therapy.
https://immattersacp.org/weekly/archives/2016/12/13/4.htm
13 Dec 2016